Yesterday, teprotumumab-trbw (Tepezza) was FDA-approved for the treatment of thyroid eye disease; a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis).